U.S. Markets open in 54 mins

NetNoggin® releases exploratory analysis "Alzheimer's Recent Drug Failures"

NetNoggin® analyzes big data to better understand why Alzheimer's drugs fail clinical trials and how the Alzheimer's community reacts to the failures.

FREDERICK, Md., Oct. 2, 2019 /PRNewswire/ -- An exploratory study, conducted by NetNoggin®, revealed that among those impacted by Alzheimer's, hope of finding a cure is deflating due to recent Alzheimer's clinical trial failures in the past few years:

Inspired by the consumer. (PRNewsfoto/NetNoggin)
  • January 2018 - Pfizer pulled out of the Alzheimer's space
  • January 2018 - Eli Lilly/AstraZeneca abandoned lanabecestat
  • February 2018 - Merck abandoned verubecestat
  • January 2019 - Roche stopped crenezumab trials
  • March 2019 - Biogen/Eisai discontinued aducanumab trials
  • July 2019 - Amgen/Novartis halted trials for CNP520
  • September 2019 - Neurotrope failed to meet Bryostatin-1 primary endpoints

In fact, the last successful Alzheimer's drug approval was in 2014 for NAMZARIC. Manufacturers acknowledge current drugs for Alzheimer's only treat symptoms as the disease continues to progress.

In response to news regarding failed clinical trials, caregivers are posting responses claiming this news makes them "depressed' and "pessimistic".  Yet, researchers and foundations remain hopeful despite the failures. For example, George Vradenburg, the head of USAgainstAlzheimers, posted on Twitter, "Let's keep failing ... until we succeed … [help] us all to remain hopeful in the fight against #Alz."

Results from NetNoggin's analysis also show growing concern that the amyloid hypothesis may be the wrong target and other mechanisms should be considered. The community suggests the following next steps:

  • Continue to research amyloids as a target (learning from failures)
  • Consider prevention as the best way to treat Alzheimer's
  • Further research BACE inhibitors with lower doses and at earlier disease stages
  • Explore the failed cancer drug, farnesyltransferase inhibitors, for Alzheimer's
  • Consider personalizing treatment (genetic research on CHRFAM7A genotype)
  • Continue to research other mechanisms and pathways of Alzheimer's

Visit https://netnoggin.net/exploratory-analysis to request the full exploratory analysis.

About NetNoggin®
NetNoggin®, a subsidiary of Conger Consulting, LLC, is a premier market research agency that specializes in pharmaceutical marketing. NetNoggin® utilizes netnography to analyze and provide context to Big Data. By leveraging 30+ years of experience, their proprietary process derives strategic consulting insights from Big Data to inform Foundational Marketing Tools (FMTs), strategies, and tactics. NetNoggin® has expertise in market research; commercial, market, and clinical development; and communications to provide reliable research, presentations, and workshops.

NetNoggin® Media Relations
If you would like more information on this topic, please contact Megan Newcomer.
E-mail: megan.newcomer@netnoggin.net

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/netnoggin-releases-exploratory-analysis-alzheimers-recent-drug-failures-300930053.html